Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.carrev.2024.07.014 | DOI Listing |
Neuroimage
January 2025
Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Front Psychiatry
December 2024
Department of Psychiatry and Psychotherapy II, Bezirkskrankenhaus Günzburg, University of Ulm, Ulm, Germany.
Front Public Health
December 2024
School of Interdisciplinary Research and Graduate Studies, College of Graduate Studies, University of South Africa, Pretoria, South Africa.
Introduction: Chronic diseases, including cardiovascular disease, diabetes, cancer, and chronic respiratory diseases, are a growing public health concern in low-and middle-income countries (LMICs) among the older population. The current review aimed to identify the main barriers that impede researchers from sharing research data on the prevention of chronic diseases in older adults living in LMICs). The review included both older women and men from these countries.
View Article and Find Full Text PDFFront Vet Sci
November 2024
Departamento de Sanidad Animal, Instituto de Ganadería de Montaña (IGM) CSIC-ULE, León, Spain.
Paratuberculosis is a chronic granulomatous enteritis, caused by subspecies (), that affects ruminants worldwide. Vaccination has been considered the most cost-effective method for the control of this disease in infected dairy herds. However, currently available vaccines do not provide complete protection and interfere with the diagnosis of both paratuberculosis and bovine tuberculosis, limiting its use.
View Article and Find Full Text PDFAntiviral Res
January 2025
Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address:
Advancement of vaccine candidates that demonstrate protective efficacy in screening studies necessitates detailed safety and immunogenicity investigations in pre-clinical models. A non-spreading Crimean-Congo hemorrhagic fever virus (CCHFV) viral replicon particle (VRP) vaccine was developed for single-dose administration to protect against disease. To date, several studies have supported safety, immunogenicity, and efficacy of the CCHF VRP in multiple highly sensitive murine models of lethal disease, but the VRP had yet to be evaluated in large animals.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!